BioMarin makes treatments for rare genetic diseases.
BioMarin Pharmaceutical Inc. (BMRN) is expected to report earnings on Monday, October 26, 2026, after the close. Estimated release time 16:07 ET. Consensus EPS estimate is $1.35.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-06 | Jun 2026 qtr | $0.95 | $1.20 | — | $989.71M |
| 2026-05-05 | Mar 2026 qtr | $0.78 | $0.55 | — | $766.21M |
| 2026-02-23 | Dec 2025 qtr | $0.17 | $-0.24 | — | $874.57M |
| 2025-10-28 | Sep 2025 qtr | $-0.15 | $-0.16 | -6.7% | $776.13M |
| 2025-08-05 | Jun 2025 qtr | $0.86 | $1.25 | — | $825.41M |
| 2025-05-02 | Mar 2025 qtr | $0.71 | $0.97 | — | $745.14M |
| 2025-02-19 | Dec 2024 qtr | $0.54 | $0.66 | — | $747.31M |
| 2024-10-29 | Sep 2024 qtr | $0.53 | $0.57 | +7.3% | $745.74M |
BMRN has beaten consensus EPS in 1 of its last 2 scored quarters.
See BMRN on the live calendar →